ERYKINE RECOMBINANT HUMAN ERYTHROPOIETIN INJECTION

Get a Price/Quote

MOQ : 1 Container

ERYKINE RECOMBINANT HUMAN ERYTHROPOIETIN INJECTION Specification

Indication
Anemia due to chronic kidney disease, chemotherapy, or HIV treatment

Origin of Medicine
Biotechnology-derived (recombinant DNA technology)

Salt Composition
Erythropoietin (r-HuEPO)

Dosage Form
Injection

Pacakaging (Quantity Per Box)
One vial per box

Drug Type
Allopathic

Ingredients
Recombinant Human Erythropoietin

Physical Form
Injection

Function
Stimulates erythropoiesis (production of red blood cells)

Recommended For
Treatment of anemia associated with chronic renal failure, cancer chemotherapy, and HIV infection

Dosage
As prescribed by physician, typically ranging from 20 IU/kg to 40 IU/kg, three times a week

Dosage Guidelines
Administered intravenously or subcutaneously as per physicians recommendation

Suitable For
Adults and children (under medical supervision)

Quantity
1 vial

Storage Instructions
Store at 2C to 8C. Do not freeze.

Color
Clear, colorless solution

Use Under Medical Supervision
Strictly under physician guidance

Packaging Type
Vial

Administration Route
Intravenous or Subcutaneous

Shelf Life
24 months from date of manufacture

Marketed By
Marketed by Alkem Laboratories

Therapeutic Category
Hematopoietic agent

Strength
2000 IU/ml (available strengths may vary from 1000 IU/ml to 10000 IU/ml)

Excipients
Buffer, Sodium chloride, Human albumin

Contraindications
Uncontrolled hypertension, hypersensitivity to erythropoietin or excipients

Side Effects
Headache, hypertension, fever, injection site reactions

Prescription Required
Yes

Regulatory Approval
Approved under CDSCO guidelines

ERYKINE RECOMBINANT HUMAN ERYTHROPOIETIN INJECTION Trade Information

Minimum Order Quantity
1 Container

Packaging Details
PACK OF 40000 IU/1.0ml

Main Domestic Market
All India

About ERYKINE RECOMBINANT HUMAN ERYTHROPOIETIN INJECTION

Grab the invincible ERYKINE Recombinant Human Erythropoietin Injection, designed for champion performance in treating anemia linked to chronic renal failure, HIV, or chemotherapy. Experience first-rate efficacy with fresh formulation, available in strengths from 1000 IU/ml to 10000 IU/ml. Conveniently packaged in a clear vial for instant checkout, this biotechnology-derived solution ensures safe administration and consistent results. Approved by CDSCO and marketed by Alkem Laboratories, ERYKINE must be used under strict medical supervision. Each dose works to stimulate erythropoiesis, restoring vitality to both adults and children.

Site Of Application, Usage Type & Direction Of Use

ERYKINE Recombinant Human Erythropoietin Injection is administered either intravenously or subcutaneously. Suitable for use in both adults and children, the injection must be used under strict medical supervision. To achieve optimal results, follow the dosage guidelines as prescribed by your physician, usually three times a week. Medical professionals should determine the individual dosage and route based on patient requirements, ensuring safe and precise application at clinical or hospital settings.

Export Market, Payment Terms & Certifications

ERYKINE Recombinant Human Erythropoietin Injection is handed over for shipment primarily to key export markets such as Asia, Africa, and the Middle East. Handover procedures require prompt and secure fulfillment under robust export documentation. Accepted payment terms include advance payments and established credit mechanisms. Each shipment is accompanied by regulatory certifications, including CDSCO approval, ensuring a secure and compliant trade process for distributors, suppliers, and wholesalers.

FAQs of ERYKINE RECOMBINANT HUMAN ERYTHROPOIETIN INJECTION:

Q: How is ERYKINE Recombinant Human Erythropoietin Injection administered?

A: ERYKINE can be administered intravenously or subcutaneously, strictly under a physicians supervision within clinical or hospital settings.

Q: What are the recommended indications for using ERYKINE Injection?

A: ERYKINE is recommended for the treatment of anemia associated with chronic renal failure, cancer chemotherapy, and HIV infection.

Q: When should a patient avoid using ERYKINE?

A: Patients with uncontrolled hypertension or hypersensitivity to erythropoietin or its excipients should avoid the use of ERYKINE Injection.

Q: Where should ERYKINE Injection be stored?

A: Store ERYKINE between 2C to 8C. Do not freeze the vial. Keep it out of reach of children and use only as directed by a physician.

Q: What is the process for exporting ERYKINE Injection?

A: The process involves handing over certified products to shipment agents, meeting CDSCO regulatory approval and export documentation requirements for legal and safe international trade.